- Home
- THRY vs NBP Comparison
THRY vs NBP Comparison
Compare THRY & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | THRY | NBP |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.3M | 173.5M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | THRY | NBP |
|---|---|---|
| Price | $4.18 | $1.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $9.33 | $9.00 |
| AVG Volume (30 Days) | ★ 584.0K | 460.0K |
| Earning Date | 04-30-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.50 | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $785,015,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $37.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.91 | $1.46 |
| 52 Week High | $14.28 | $5.19 |
Technical Indicators
Market Signals| Indicator | THRY | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 61.50 | 42.77 |
| Support Level | $3.14 | N/A |
| Resistance Level | $6.27 | $1.67 |
| Average True Range (ATR) | 0.23 | 0.11 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 98.80 | 72.23 |
Price Performance
Historical ComparisonAbout THRY Thryv Holdings Inc.
Thryv Holdings Inc is dedicated to supporting local, independent service-based businesses and emerging franchises by providing a cloud-based software platform, and marketing solutions to entrepreneurs. The group are provider of SaaS all-in-one small business management software in addition to providing print and digital marketing solutions to SMBs. Its solutions enable small and medium-sized business clients to attract and generate new business leads, manage their customer relationships efficiently with artificial intelligence (AI) tools and automation. The group has two business segments; Thryv SaaS deriving maximum revenue and Thryv Marketing Services.
About NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.